Alkermes Plc Mural Oncology Call Transcript
Good day, everyone, and welcome to the Mural Oncology Investor Call. Today's call is being recorded. At this time, I'd like to turn the call over to Dave Bora. Please go ahead.
Hello, and welcome to Mural Oncology's investor presentation. I'm Dave Bora, SVP of IR and Corporate Affairs from Mural, and I'm pleased to be joined by CEO, Caroline Loew VP Clinical Research Oncology, Jessicca Rege; Director of R&D, Josh Heiber and Principal Scientist, Mark Whitmore. We look forward to telling you more about Mural is protein engineering capabilities, how our lead asset in nemvaleukin differs from other IL-2 approaches, now are exciting candidates in our pipeline. We'll leave time at the end for Q&A as well.
Today, we'll be making forward-looking statements about our business, including our pipeline assets. Just to note, of course, that this is an inherently risky business, and we do our best to articulate the risk that we face but for more information we'd always point you to our SEC disclosures.
Here's a look at
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |